Eyelid Melanoma in the United States: A National Cancer Database Analysis

Jeremie D. Oliver, Daniel Boczar, Andrea Sisti, Maria T. Huayllani, David J. Restrepo, Aaron C. Spaulding, Emmanuel Gabriel, Sanjay Bagaria, Brian D. Rinker, Antonio J. Forte

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Eyelid melanoma (EM) is a rare condition that accounts for <1% of all cutaneous melanomas. In this analysis, patients diagnosed with EM in the United States were compared to those with other melanomas in the head and neck. METHODS: The National Cancer Database was used to select patients with head and neck melanoma from 2004 to 2015. RESULTS: A total of 137,233 patients met the criteria of the study. Among them, 2694 were diagnosed with EM (2%) and 134,539 in other head and neck locations (98%). Regarding the patients with EM, the mean age was 68.56 years (standard deviation 14.04). A greater number of them were treated in Academic/Research Programs (53.6%), insured by Medicare (55.7%), tumor in situ (52.2%), stage 0 (49%), and without ulceration (75.9%). The mean time to treatment commencement was 18.96 days for EM compared to 14.4 days for other melanoma in the head and neck regions (P < 0.001). There was a greater proportion of EM in female patients (odds ratio [OR] 2.371 [2.191-2.566], P < 0.001), compared to male; age greater than 80 years (OR 1.622 [1.360-1.934], P < 0.001) compared to 0 to 49 years. Moreover, EM was an independent predictor for treatment in Academic/Research Programs (OR 1.258 [1.160-1.365], P < 0.001) and diagnosis at autopsy (OR 1.414 [1.083-1.847], P = 0.011) compared to other melanoma in the head and neck region. CONCLUSION: These novel findings have the potential to guide clinical decision making in head and neck melanoma management.

Original languageEnglish (US)
Pages (from-to)2412-2415
Number of pages4
JournalThe Journal of craniofacial surgery
Volume30
Issue number8
DOIs
StatePublished - Nov 1 2019

Fingerprint

Eyelids
Melanoma
Databases
Neoplasms
Neck
Head
Odds Ratio
Medicare
Research
Autopsy

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Oliver, J. D., Boczar, D., Sisti, A., Huayllani, M. T., Restrepo, D. J., Spaulding, A. C., ... Forte, A. J. (2019). Eyelid Melanoma in the United States: A National Cancer Database Analysis. The Journal of craniofacial surgery, 30(8), 2412-2415. https://doi.org/10.1097/SCS.0000000000005673

Eyelid Melanoma in the United States : A National Cancer Database Analysis. / Oliver, Jeremie D.; Boczar, Daniel; Sisti, Andrea; Huayllani, Maria T.; Restrepo, David J.; Spaulding, Aaron C.; Gabriel, Emmanuel; Bagaria, Sanjay; Rinker, Brian D.; Forte, Antonio J.

In: The Journal of craniofacial surgery, Vol. 30, No. 8, 01.11.2019, p. 2412-2415.

Research output: Contribution to journalArticle

Oliver, JD, Boczar, D, Sisti, A, Huayllani, MT, Restrepo, DJ, Spaulding, AC, Gabriel, E, Bagaria, S, Rinker, BD & Forte, AJ 2019, 'Eyelid Melanoma in the United States: A National Cancer Database Analysis', The Journal of craniofacial surgery, vol. 30, no. 8, pp. 2412-2415. https://doi.org/10.1097/SCS.0000000000005673
Oliver, Jeremie D. ; Boczar, Daniel ; Sisti, Andrea ; Huayllani, Maria T. ; Restrepo, David J. ; Spaulding, Aaron C. ; Gabriel, Emmanuel ; Bagaria, Sanjay ; Rinker, Brian D. ; Forte, Antonio J. / Eyelid Melanoma in the United States : A National Cancer Database Analysis. In: The Journal of craniofacial surgery. 2019 ; Vol. 30, No. 8. pp. 2412-2415.
@article{efcd01b058964cd29bc12d55d7cc8c0e,
title = "Eyelid Melanoma in the United States: A National Cancer Database Analysis",
abstract = "BACKGROUND: Eyelid melanoma (EM) is a rare condition that accounts for <1{\%} of all cutaneous melanomas. In this analysis, patients diagnosed with EM in the United States were compared to those with other melanomas in the head and neck. METHODS: The National Cancer Database was used to select patients with head and neck melanoma from 2004 to 2015. RESULTS: A total of 137,233 patients met the criteria of the study. Among them, 2694 were diagnosed with EM (2{\%}) and 134,539 in other head and neck locations (98{\%}). Regarding the patients with EM, the mean age was 68.56 years (standard deviation 14.04). A greater number of them were treated in Academic/Research Programs (53.6{\%}), insured by Medicare (55.7{\%}), tumor in situ (52.2{\%}), stage 0 (49{\%}), and without ulceration (75.9{\%}). The mean time to treatment commencement was 18.96 days for EM compared to 14.4 days for other melanoma in the head and neck regions (P < 0.001). There was a greater proportion of EM in female patients (odds ratio [OR] 2.371 [2.191-2.566], P < 0.001), compared to male; age greater than 80 years (OR 1.622 [1.360-1.934], P < 0.001) compared to 0 to 49 years. Moreover, EM was an independent predictor for treatment in Academic/Research Programs (OR 1.258 [1.160-1.365], P < 0.001) and diagnosis at autopsy (OR 1.414 [1.083-1.847], P = 0.011) compared to other melanoma in the head and neck region. CONCLUSION: These novel findings have the potential to guide clinical decision making in head and neck melanoma management.",
author = "Oliver, {Jeremie D.} and Daniel Boczar and Andrea Sisti and Huayllani, {Maria T.} and Restrepo, {David J.} and Spaulding, {Aaron C.} and Emmanuel Gabriel and Sanjay Bagaria and Rinker, {Brian D.} and Forte, {Antonio J.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/SCS.0000000000005673",
language = "English (US)",
volume = "30",
pages = "2412--2415",
journal = "Journal of Craniofacial Surgery",
issn = "1049-2275",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Eyelid Melanoma in the United States

T2 - A National Cancer Database Analysis

AU - Oliver, Jeremie D.

AU - Boczar, Daniel

AU - Sisti, Andrea

AU - Huayllani, Maria T.

AU - Restrepo, David J.

AU - Spaulding, Aaron C.

AU - Gabriel, Emmanuel

AU - Bagaria, Sanjay

AU - Rinker, Brian D.

AU - Forte, Antonio J.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND: Eyelid melanoma (EM) is a rare condition that accounts for <1% of all cutaneous melanomas. In this analysis, patients diagnosed with EM in the United States were compared to those with other melanomas in the head and neck. METHODS: The National Cancer Database was used to select patients with head and neck melanoma from 2004 to 2015. RESULTS: A total of 137,233 patients met the criteria of the study. Among them, 2694 were diagnosed with EM (2%) and 134,539 in other head and neck locations (98%). Regarding the patients with EM, the mean age was 68.56 years (standard deviation 14.04). A greater number of them were treated in Academic/Research Programs (53.6%), insured by Medicare (55.7%), tumor in situ (52.2%), stage 0 (49%), and without ulceration (75.9%). The mean time to treatment commencement was 18.96 days for EM compared to 14.4 days for other melanoma in the head and neck regions (P < 0.001). There was a greater proportion of EM in female patients (odds ratio [OR] 2.371 [2.191-2.566], P < 0.001), compared to male; age greater than 80 years (OR 1.622 [1.360-1.934], P < 0.001) compared to 0 to 49 years. Moreover, EM was an independent predictor for treatment in Academic/Research Programs (OR 1.258 [1.160-1.365], P < 0.001) and diagnosis at autopsy (OR 1.414 [1.083-1.847], P = 0.011) compared to other melanoma in the head and neck region. CONCLUSION: These novel findings have the potential to guide clinical decision making in head and neck melanoma management.

AB - BACKGROUND: Eyelid melanoma (EM) is a rare condition that accounts for <1% of all cutaneous melanomas. In this analysis, patients diagnosed with EM in the United States were compared to those with other melanomas in the head and neck. METHODS: The National Cancer Database was used to select patients with head and neck melanoma from 2004 to 2015. RESULTS: A total of 137,233 patients met the criteria of the study. Among them, 2694 were diagnosed with EM (2%) and 134,539 in other head and neck locations (98%). Regarding the patients with EM, the mean age was 68.56 years (standard deviation 14.04). A greater number of them were treated in Academic/Research Programs (53.6%), insured by Medicare (55.7%), tumor in situ (52.2%), stage 0 (49%), and without ulceration (75.9%). The mean time to treatment commencement was 18.96 days for EM compared to 14.4 days for other melanoma in the head and neck regions (P < 0.001). There was a greater proportion of EM in female patients (odds ratio [OR] 2.371 [2.191-2.566], P < 0.001), compared to male; age greater than 80 years (OR 1.622 [1.360-1.934], P < 0.001) compared to 0 to 49 years. Moreover, EM was an independent predictor for treatment in Academic/Research Programs (OR 1.258 [1.160-1.365], P < 0.001) and diagnosis at autopsy (OR 1.414 [1.083-1.847], P = 0.011) compared to other melanoma in the head and neck region. CONCLUSION: These novel findings have the potential to guide clinical decision making in head and neck melanoma management.

UR - http://www.scopus.com/inward/record.url?scp=85074552757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074552757&partnerID=8YFLogxK

U2 - 10.1097/SCS.0000000000005673

DO - 10.1097/SCS.0000000000005673

M3 - Article

C2 - 31233000

AN - SCOPUS:85074552757

VL - 30

SP - 2412

EP - 2415

JO - Journal of Craniofacial Surgery

JF - Journal of Craniofacial Surgery

SN - 1049-2275

IS - 8

ER -